FDA Halts One of the First Human CRISPR Studies Before it Begins
FDA Halts One of the First Human CRISPR Studies Before it Begins
Published on May 31, 2018 at 02:40PM
A trial planning to use the gene-editing tool CRISPR on sickle cell patients has been put on hold due to unspecified questions from US regulators. From a report: CRISPR Therapeutics, which is developing the therapy, sought approval from the US Food and Drug Administration in April to begin the study. The therapy involves extracting stem cells from a patient's bone marrow and editing them with CRISPR in the lab. Once infused back into the patient, the idea is that the edited cells would give rise to healthy red blood cells. But according to a statement on Wednesday from CRISPR Therapeutics, the FDA ordered the company not to proceed with its study until it answers questions about its CRISPR treatment.
Hope you like this please comment your view and share to your friends thanks for visiting bye guys meet you in next post
Published on May 31, 2018 at 02:40PM
A trial planning to use the gene-editing tool CRISPR on sickle cell patients has been put on hold due to unspecified questions from US regulators. From a report: CRISPR Therapeutics, which is developing the therapy, sought approval from the US Food and Drug Administration in April to begin the study. The therapy involves extracting stem cells from a patient's bone marrow and editing them with CRISPR in the lab. Once infused back into the patient, the idea is that the edited cells would give rise to healthy red blood cells. But according to a statement on Wednesday from CRISPR Therapeutics, the FDA ordered the company not to proceed with its study until it answers questions about its CRISPR treatment.
Read more of this story at Slashdot.
Hope you like this please comment your view and share to your friends thanks for visiting bye guys meet you in next post
FDA Halts One of the First Human CRISPR Studies Before it Begins
![FDA Halts One of the First Human CRISPR Studies Before it Begins]()
Reviewed by Kartik
on
May 31, 2018
Rating:
No comments: